Skip to content

Screener

Eligibility screening

A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) na…

Sponsored by SynAct Pharma ApsStudy detailsClinicalTrials.gov

3 US sites in FL, PA

Before we begin

Who are you filling this out for?

Your answer affects how the questions are phrased.